Clinical Trial Update: A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia. [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and pharmacokinetics of RO6839921 (idasanutlin), an MDM2 antagonist, in patients with advanced cancers including acute myeloid le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Idasanutlin (Idasanutlin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms, Myelogenous Leukemia, Acute | Phase 1 | Status: COMPLETED